GlassScriptPhysician profile
Cindy M Mcadams
NPI 1306829759
$3,760.18
in general payments reported to CMS, 2019-2025
28 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $146 · 2021: $374 · 2022: $576 · 2023: $737 · 2024: $427 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.92 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $824.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $428.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $243.71 | 2019-2021 | |
| Amgen INC. | $221.72 | 2019-2024 | Otezla, Repatha |
| Astellas Pharma US INC | $204.26 | 2023-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $199.13 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $198.08 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.16 | 2019-2022 | |
| Pfizer INC. | $172.30 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $161.78 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.72 | 2019-2023 | Tradjenta, Trijardy Xr, Glyxambi |
| Abbvie INC. | $156.82 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $110.00 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $73.92 | 2019-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $61.72 | 2023-2024 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $60.71 | 2025 | Heplisav-B |
| Inspire Medical Systems, INC. | $41.95 | 2024 | Inspire |
| Abbott Laboratories | $36.75 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $31.16 | 2025 | Contrave, Onzetra Xsail |
| Janssen Pharmaceuticals, INC | $29.01 | 2019 | |
| Genentech USA, INC. | $27.32 | 2019-2021 | |
| Intra-Sana Laboratories | $25.76 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Otsuka America Pharmaceutical, INC. | $21.17 | 2021 | |
| Ibsa Pharma INC. | $20.55 | 2020 | |
| Amarin Pharma, INC. | $16.87 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.41 | 2023 | Voquezna |
| Axsome Therapeutics, INC. | $14.17 | 2024 | Auvelity |
| Allergan, INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Mcadams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.